Point-of-Care Diagnostics Market Size & Growth Forecast 2027–2036, By Segments (Product, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Point-of-Care Diagnostics Market size was worth USD 22.64 billion in 2026 and is expected to grow at a 3.9% CAGR between 2027 and 2036, reaching USD 33.19 billion by 2036. The industry revenue for 2027 is calculated at USD 23.38 billion.
Get more details on this report
Request Free Sample ReportPoint-of-Care Diagnostics Market Intelligence Snapshot
Regional Market Dynamics
- North America holds 47.03% share driven by widespread rapid testing adoption across hospitals, urgent care, and clinics, supported by reimbursement pathways and established decentralized diagnostic workflows.
- Asia Pacific growth at 7.01% CAGR is supported by expanding healthcare access, rising point-of-care deployment in urban and underserved areas, and demand for faster diagnostic turnaround.
Segment Momentum
- Glucose/diabetes monitoring accounted for 32.36% of the market in 2026 because routine diabetes management requires frequent, rapid testing, creating consistent demand across clinical and near-patient settings.
- Home is the fastest-growing segment because patients increasingly prefer convenient, accessible testing that supports regular monitoring and early detection without requiring frequent visits to healthcare facilities.
Market Expansion Drivers
- Rising geriatric population increasing demand for rapid decentralized diagnostic testing solutions.
- Growing prevalence of infectious and genetic diseases accelerating adoption of point-of-care diagnostics.
- Expanding mobile diagnostic device deployment improving healthcare accessibility in middle-income countries.
Leading Market Participants
- Major companies in the point-of-care diagnostics market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (United States), Becton, Dickinson and Company (United States), QIAGEN N.V. (Netherlands), bioMérieux SA (France), QuidelOrtho Corporation (United States), Werfen, S.A. (Spain), Nova Biomedical Corporation (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 22.64 billion
- 2027 Estimated Market Size: USD 23.38 billion.
- Projected Market Size: USD 33.19 billion by 2036
- Growth Forecast: 3.9% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Glucose/Diabetes Monitoring (Product) | Clinics (End-use)
- Emerging Opportunity Segment: Infectious Disease Testing (Product) | Home (End-use)
Market Growth Drivers and Industry Trends
Rising geriatric population increasing demand for rapid decentralized diagnostic testing solutions
The growing geriatric population is creating greater demand for accessible and timely healthcare testing, which will drive the point-of-care diagnostics market as older patients require more frequent monitoring and diagnostic evaluation. Age-related conditions often involve recurring assessments of blood glucose, cardiac indicators, infections, and other health parameters, making rapid testing near the patient particularly valuable. Decentralized diagnostic solutions can reduce dependence on centralized laboratories, shorten waiting periods, and support quicker clinical decisions in hospitals, outpatient facilities, and community healthcare settings. Their portability and ease of use also make them suitable for elderly patients who may face mobility limitations or require repeated testing during routine care and chronic disease management.
Growing prevalence of infectious and genetic diseases accelerating adoption of point-of-care diagnostics
The increasing burden of infectious and genetic diseases is strengthening demand for faster diagnostic pathways, thereby propelling the point-of-care diagnostics market through broader use of rapid testing technologies. Point-of-care platforms enable healthcare professionals to obtain clinically relevant results closer to the site of treatment, supporting earlier identification and management of diseases where timely intervention is important. Advances in molecular diagnostics, nucleic acid testing, and compact assay technologies are expanding the range of conditions that can be evaluated outside conventional laboratories. Greater utilization across emergency care, primary healthcare, and decentralized screening environments is also encouraging healthcare providers to incorporate rapid diagnostic testing into routine clinical workflows.
Expanding mobile diagnostic device deployment improving healthcare accessibility in middle-income countries
Deployment of portable and mobile diagnostic devices across underserved areas is creating new opportunities for the point-of-care diagnostics market by extending testing capabilities beyond conventional healthcare facilities. Middle-income countries often face uneven distribution of laboratories, limited diagnostic infrastructure, and long travel distances for patients in rural or remote communities. Compact devices that can operate with limited infrastructure allow healthcare workers to conduct testing at community clinics, outreach programs, and mobile healthcare units, supporting earlier diagnosis and treatment decisions. Improvements in device portability, battery operation, connectivity, and simplified workflows are further enabling mobile diagnostic services to function in settings where conventional laboratory equipment may be difficult to install or maintain.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising geriatric population increasing demand for rapid decentralized diagnostic testing solutions | 1.90% | High | North America, Asia Pacific | High | Near Term |
| Growing prevalence of infectious and genetic diseases accelerating adoption of point-of-care diagnostics | 1.80% | High | North America, Europe | High | Mid Term |
| Expanding mobile diagnostic device deployment improving healthcare accessibility in middle-income countries | 1.40% | Moderate | Asia Pacific, Latin America | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the point-of-care diagnostics market, North America held the largest share of 47.03% in 2026, supported by advanced healthcare infrastructure, widespread adoption of decentralized testing, and strong demand for rapid clinical decision-making. Hospitals, physician offices, emergency care settings, and other healthcare facilities increasingly rely on near-patient diagnostic technologies to shorten testing cycles and support timely treatment. High healthcare technology adoption, established reimbursement frameworks, and continued investment in diagnostic innovation further strengthen regional demand. The integration of connected diagnostic devices with electronic health records and digital healthcare platforms is also improving workflow efficiency and enabling healthcare professionals to access test results more quickly, reinforcing the region's leading position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing regional market, driven by expanding healthcare access, rising demand for affordable and rapid testing, and increasing investment in decentralized medical infrastructure. Large and diverse patient populations, particularly across emerging economies, are encouraging healthcare providers to adopt diagnostic solutions that can operate effectively outside centralized laboratories. Growing emphasis on early disease detection, infectious disease management, maternal and chronic care, and rural healthcare delivery is creating additional opportunities for point-of-care technologies. Improvements in healthcare infrastructure, greater availability of portable diagnostic platforms, and increasing digital connectivity are further supporting adoption, while efforts to improve healthcare accessibility are strengthening the region's long-term growth prospects.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Diagnostic WorkflowsGermany prioritizes point-of-care diagnostic solutions that deliver reliable results while integrating with established laboratory and clinical systems. German healthcare providers increasingly adopt advanced testing platforms that improve operational efficiency without compromising diagnostic accuracy.
France 🇫🇷
Decentralized Care SupportFrance expands the use of point-of-care diagnostics to strengthen primary care, emergency services, and community-based testing. French healthcare providers prioritize dependable testing solutions that enable faster treatment decisions and improved coordination across care settings.
Italy 🇮🇹
Accessible Clinical TestingItaly continues adopting point-of-care diagnostics to enhance testing availability in hospitals, outpatient clinics, and regional healthcare facilities. Italian healthcare organizations focus on practical diagnostic platforms that improve workflow efficiency while supporting timely patient management.
Japan 🇯🇵
Compact Testing SolutionsJapan favors compact point-of-care diagnostic devices suited for hospitals, outpatient facilities, and community healthcare environments. Japanese manufacturers continue refining user-friendly testing technologies that support timely diagnosis while minimizing operational complexity.
South Korea 🇰🇷
Digital Diagnostics IntegrationSouth Korea combines point-of-care diagnostics with digital healthcare platforms to improve test accessibility and clinical responsiveness. South Korean healthcare providers emphasize connected diagnostic systems that streamline data management and support efficient patient care workflows.
United States 🇺🇸
Rapid Clinical TestingThe U.S. point-of-care diagnostics market emphasizes fast and decentralized testing across hospitals, clinics, pharmacies, and home healthcare settings. Healthcare providers in the U.S. increasingly adopt portable diagnostic technologies that accelerate clinical decision-making and improve patient convenience.
Segment Leadership and Growth Trends
Point-of-Care Diagnostics Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Glucose/Diabetes Monitoring (Largest Segment) vs Infectious Disease Testing (Fastest-Growing Segment)
The glucose/diabetes monitoring segment dominated the point-of-care diagnostics market with a 32.36% share in 2026, reflecting the persistent need for convenient and rapid monitoring of blood glucose levels. Point-of-care glucose testing supports frequent assessment outside centralized laboratories, enabling patients and healthcare professionals to make timely treatment and disease-management decisions. The widespread need for ongoing diabetes management, combined with increasing emphasis on self-monitoring and decentralized healthcare, continues to sustain demand for glucose testing products. Advances in portable diagnostic technologies and easier access to monitoring tools further strengthen the segment's established position.
Infectious disease testing is the fastest-growing product segment, supported by increasing demand for rapid diagnostic results that can guide timely clinical decisions. Point-of-care testing enables infections to be assessed closer to the patient, reducing dependence on centralized laboratory workflows and helping healthcare professionals respond more quickly when treatment or isolation decisions are required. Greater emphasis on early detection, infection control, and decentralized diagnostics is expanding the role of rapid infectious disease testing across healthcare settings. Improvements in test portability, usability, and diagnostic performance are further encouraging adoption as healthcare systems seek faster and more accessible testing solutions.
End-use Segment Analysis: Clinics (Largest Segment) vs Home (Fastest-Growing Segment)
The clinics segment held the largest share of the point-of-care diagnostics market in 2026, reflecting the importance of outpatient clinical environments in delivering rapid diagnostic services. Clinics benefit from point-of-care technologies because testing can be performed close to the patient, allowing healthcare professionals to obtain results during consultations and make treatment decisions without waiting for centralized laboratory processing. The growing preference for efficient outpatient care and the need to streamline diagnostic workflows continue to support the use of point-of-care systems in clinics. Their ability to combine diagnostic testing with immediate clinical assessment makes this end-use setting particularly well suited to decentralized diagnostics.
Home is the fastest-growing end-use segment as healthcare increasingly shifts toward patient-centered monitoring and decentralized disease management. Home-based point-of-care diagnostics allow individuals to conduct selected tests conveniently outside traditional healthcare facilities, supporting regular monitoring and earlier recognition of potential health changes. The expansion of remote healthcare services and growing consumer interest in self-management are creating stronger demand for simple, portable, and user-friendly diagnostic devices. Greater integration of home testing with digital health and remote-care workflows is also reinforcing the role of the home environment as an important growth area for point-of-care diagnostics.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Glucose/Diabetes Monitoring, Cardiometabolic & Blood Gas, Infectious Disease Testing, Coagulation Monitoring, Pregnancy & Fertility Testing, Urinalysis & Nephrology, Hematology Testing, Tumor/Cancer Markers, Toxicology/Drug of Abuse, Others | Glucose/Diabetes Monitoring | Infectious Disease Testing |
| End-use | Clinics, Hospitals, Home, Assisted Living Healthcare Facilities, Laboratory | Clinics | Home |
Competitive Landscape and Market Positioning
Top players in the point-of-care diagnostics market:
1. Abbott Laboratories (United States)
2. F. Hoffmann-La Roche Ltd (Switzerland)
3. Siemens Healthineers AG (Germany)
4. Danaher Corporation (United States)
5. Becton Dickinson and Company (United States)
6. QIAGEN N.V. (Netherlands)
7. bioMérieux SA (France)
8. QuidelOrtho Corporation (United States)
9. Werfen S.A. (Spain)
10. Nova Biomedical Corporation (United States)
The point-of-care diagnostics market is evolving through rapid testing technologies and decentralized healthcare solutions. Innovation is improving diagnostic speed and accuracy. Collaborative development is strengthening healthcare accessibility. Continuous advancement is supporting early disease detection capabilities.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| F. Hoffmann-La Roche Ltd (Switzerland) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| Danaher Corporation (United States) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| QIAGEN N.V. (Netherlands) | |||||||
| bioMérieux SA (France) | |||||||
| QuidelOrtho Corporation (United States) | |||||||
| Werfen S.A. (Spain) | |||||||
| Nova Biomedical Corporation (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Siemens Healthineers | Jan-26 | Siemens Healthineers launched a strategic collaboration to integrate portable on-field imaging into athletic environments. By enabling immediate diagnostic assessment and injury triage, the initiative extends point-of-care capabilities into non-traditional, highly mobile settings, demonstrating a functional shift in how clinical decision-making is executed outside of standard healthcare facilities. |
| AISAP | Nov-25 | AISAP partnered with the G-ACT Foundation to deploy its AI-powered POCAD platform in Ghana. By integrating cloud-based echocardiogram interpretation in low-resource environments, the initiative scales expert-level cardiac diagnostics, effectively addressing workforce shortages and establishing a new model for decentralized, AI-driven molecular and imaging diagnostics. |
| Sciverse Solutions | Nov-25 | Sciverse Solutions and Bhat Biotech entered a strategic partnership to co-develop AI-enabled molecular diagnostic platforms. The collaboration focuses on advancing portable point-of-care testing technology to deliver real-time, high-accuracy clinical results, enhancing the diagnostic capabilities of decentralized healthcare providers in the Indian market. |
| Viome Life Sciences | Jul-25 | Viome Life Sciences entered a strategic collaboration with Scripps Research to validate an at-home RNA-based diagnostic test for precancerous colon polyps. This project integrates molecular diagnostics with AI analysis to shift colorectal cancer screening from traditional clinical environments to decentralized, patient-accessible settings, aiming to improve early intervention outcomes. |
| QuidelOrtho | Jun-25 | QuidelOrtho announced a strategic realignment in its molecular diagnostics business, acquiring LEX Diagnostics while discontinuing its own Savanna platform. This shift refocuses development resources to accelerate growth and optimize the company's portfolio of rapid, point-of-care testing solutions. |
| Siemens Healthineers | May-25 | Siemens Healthineers committed $150 million toward expanding its U.S. manufacturing footprint. The investment is designed to enhance supply-chain resilience and increase production capacity for diagnostic technologies, supporting the company’s ability to meet growing demand for decentralized healthcare solutions through upgraded facility infrastructure. |
| BD | Feb-25 | BD announced a major organizational restructuring, planning to spin off its Biosciences and Diagnostic Solutions units. This strategic separation is intended to sharpen operational focus, enable independent growth investments for the diagnostics business, and increase long-term competitive agility within the rapidly evolving point-of-care market. |
| bioMérieux | Jan-25 | bioMérieux acquired SpinChip Diagnostics to integrate its next-generation immunoassay platform into a global portfolio. This transaction accelerates the commercialization of high-speed, decentralized diagnostic capabilities, allowing for rapid results from small-volume blood samples and strengthening the company's competitive positioning in near-patient testing solutions. |
| Binx Health | Jan-25 | Binx Health secured $65 million in Series F financing to scale the commercial expansion of its Binx io diagnostic platform. The capital injection supports broader deployment of the company's on-demand testing technology, accelerating its adoption across clinical and outpatient settings to enhance decentralized healthcare delivery. |
| Hyperfine Inc | Nov-24 | Hyperfine Inc. secured CE mark approval for its AI-powered software upgrade for the Swoop portable MRI system. This regulatory milestone enhances bedside neuroimaging capabilities, allowing for more precise, AI-assisted diagnosis in resource-limited or decentralized clinical settings where traditional, stationary imaging is inaccessible. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Point-of-Care Diagnostics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Sample Type | Blood, Urine, Saliva, Nasal/Respiratory Specimens, Stool, Other Clinical Specimens |
| Technology | Immunoassay, Molecular Diagnostics, Clinical Chemistry, Hematology, Electrochemical Biosensing, Other Technologies |
| Connectivity | Standalone Devices, Bluetooth-Enabled Devices, Wi-Fi/Cloud-Connected Devices, Mobile/Smartphone-Connected Devices |
Point-of-Care Diagnostics Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Decentralized Healthcare Adoption Outlook |
|
| Diagnostic Reimbursement and Funding Landscape |
|
| Clinical Workflow Integration Assessment |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of point-of-care diagnostics?
What is the forecasted size of the point-of-care diagnostics industry?
How is rising geriatric care demand influencing procurement and deployment of decentralized diagnostic systems?
Why is the increasing prevalence of infectious and genetic diseases accelerating adoption of point-of-care diagnostic platforms?
Why does glucose/diabetes monitoring lead the point-of-care diagnostics market?
Why is home use the fastest-growing end-use segment in the point-of-care diagnostics market?
Why does North America dominate point-of-care diagnostics adoption?
What is driving Asia Pacific’s growth in point-of-care diagnostics?
Which companies dominate the point-of-care diagnostics landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization